Internal Medicine, Gastroenterology · San Francisco, CA
NPI
1417009630
Since 2007
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
2100 Webster St, Suite 423
San Francisco, CA, 94115
Phone (415) 923-3050
Groups this clinician bills Medicare through
Medicare paid, 2024
$104K
777 services
Medicare patients, 2024
517
Average age 74
Drug cost, 2024
$741K
1,804 prescriptions
Company payments, 2025
$3,730
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Annette Y Kwon was code 99214 (office e&m - established), 207 times for 157 patients. In total Annette Y Kwon billed 777 services in 19 codes, and Medicare paid $104K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-07-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 207 | 157 | $115.11 | $24K |
| 45380 Lower GI Endoscopy - Other | Facility | 154 | 154 | $141.96 | $22K |
| 43239 Upper GI Endoscopy | Facility | 117 | 113 | $85.74 | $10K |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 79 | 79 | $204.88 | $16K |
| 45385 Colonoscopy - Lesion Removal | Facility | 62 | 62 | $211.89 | $13K |
| 99203 Office E&M - New | Office | 54 | 54 | $95.69 | $5,167 |
| 99204 Office E&M - New | Office | 28 | 28 | $152.82 | $4,279 |
| 45378 Lower GI Endoscopy - Other | Facility | 22 | 22 | $154.66 | $3,403 |
| 99213 Office E&M - Established | Office | 21 | 18 | $76.26 | $1,601 |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 12 | 12 | $205.20 | $2,462 |
By year: 2022 $94K for 859 services; 2023 $94K for 758 services; 2024 $104K for 777 services.
Medicare prescription drug claims, 2024
In 2024, the drug Annette Y Kwon prescribed most often to Medicare patients was Omeprazole, with 247 prescriptions and refills. In total Annette Y Kwon wrote 1,804 Medicare prescriptions that cost $741K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Omeprazole Generic | 247 | 559 | 79 | $3,550 |
| Pantoprazole Sodium Generic | 199 | 456 | 64 | $3,871 |
| Famotidine Generic | 198 | 463 | 61 | $3,678 |
| Sutab Sod Sulf/Pot Chloride/Mag Sulf | 89 | 89 | 88 | $14K |
| Linzess Linaclotide | 81 | 125 | 17 | $66K |
| Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates | 76 | 76 | 76 | $4,635 |
| Creon Lipase/Protease/Amylase | 64 | 71 | 12 | $169K |
| Mesalamine Generic | 55 | 85 | 13 | $37K |
| Dexlansoprazole Dr Dexlansoprazole | 54 | 108 | 13 | $16K |
| Viberzi Eluxadoline | 38 | 50 | Under 11 | $78K |
| Lansoprazole Generic | 36 | 66 | Under 11 | $714 |
| Mesalamine Er Mesalamine | 34 | 56 | Under 11 | $4,988 |
| Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl | 32 | 32 | 32 | $514 |
| Budesonide Dr Budesonide | 31 | 57 | Under 11 | $3,187 |
| Motegrity Prucalopride Succinate | 30 | 30 | Under 11 | $17K |
Brand drugs: - claims; generic drugs: 1,306 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Annette Y Kwon $3,730 ($3,730 in general payments such as food, travel and fees) from 16 companies. The largest payer was Abbvie Inc. with $1,277.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 50 | $1,277 |
| Janssen Biotech, Inc. JNJ | 15 | $503 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 16 | $372 |
| Aimmune Therapeutics, Inc. | 8 | $224 |
| Celltrion USA Inc. 068270.KS | 8 | $203 |
| Pfizer Inc. PFE | 9 | $199 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 8 | $194 |
| Lilly USA, LLC LLY | 6 | $191 |
| Regeneron Healthcare Solutions, Inc. REGN | 4 | $128 |
| Genzyme Corporation SNY | 3 | $123 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.